Overview

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis

Status:
Not yet recruiting

Trial end date:
2023-01-18

Target enrollment:

Participant gender:

Summary

The study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of multiple orally administered TCK-276 in both males and females with Rheumatoid Arthritis (RA).

Phase:

Phase 1

Details

Lead Sponsor:

Teijin America, Inc.

Collaborator:

Parexel